Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas.

摘要: Low-grade non-Hodgkin's lymphomas (NHL) are very sensitive to a broad range of chemotherapeutic and biological agents. Relapses, however, occur even after aggressive cytostatic combinations in first-line therapy. Therefore, effective well-tolerated salvage therapies important. In this single-institution trial, the efficacy toxicity bendamustine treatment relapsed low-grade NHL was investigated. Fifty-eight patients with pretreated different regimens were included. All received at 120 mg/m(2) as 1-h infusion on 2 consecutive days. The repeated every 3 weeks until complete remission (CR), partial (PR) or stable disease (SD) confirmed two cycles. Efficacy evaluated 52 patients: CR induced 11%, PR 62% SD another 10% patients. No response seen 17%. median duration 16 months survival time 36 months. Side effects generally mild, restricted myelosuppression, gastrointestinal allergic reactions. Bendamustine proved be well tolerated primary resistant NHL.